OVID THERAPEUTICS INC (OVID)
US6904691010 - Common Stock
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment;...
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer...
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer...
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA...
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for...
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30 million non-dilutive capital infusion from...
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
3 Very Promising Penny Stocks That Are Flying Under the Radar
Although the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators.
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed...
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned...
Ovid Therapeutics Added to Russell 3000® Index
Ovid Therapeutics Added to Russell 3000® Index
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer...
Ovid Therapeutics GAAP EPS of -$0.19 misses by $0.02, revenue of $0.07M beats by $0.05M (NASDAQ:OVID)
Ovid Therapeutics press release (NASDAQ:OVID): Q1 GAAP EPS of -$0.19 misses by $0.02.Revenue of $0.07M (-95.2% Y/Y) beats by $0.05M.
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat...
Ovid to invest $10M in Graviton to license neuro disease drug candidate
Ovid Therapeutics (OVID) signed a collaboration agreement with Graviton Bioscience to develop therapies for rare neurological diseases.Ovid said the agreement supports its strategy...
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS...